NASDAQ:CPRX Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $16.12 +0.10 (+0.62%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$15.64▼$16.1750-Day Range$14.34▼$21.0552-Week Range$6.15▼$22.11Volume1.38 million shsAverage Volume2.39 million shsMarket Capitalization$1.70 billionP/E Ratio21.78Dividend YieldN/APrice Target$21.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalyst Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside33.9% Upside$21.50 Price TargetShort InterestBearish10.61% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.54Based on 20 Articles This WeekInsider TradingSelling Shares$803,500 Sold Last QuarterProj. Earnings Growth12.06%From $1.41 to $1.58 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.59 out of 5 starsMedical Sector108th out of 989 stocksPharmaceutical Preparations Industry38th out of 480 stocks 3.4 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.50, Catalyst Pharmaceuticals has a forecasted upside of 33.9% from its current price of $16.06.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.61% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 6.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 2.5 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Catalyst Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 52 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.MarketBeat FollowsOnly 16 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $803,500.00 in company stock.Percentage Held by Insiders14.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.66% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 12.06% in the coming year, from $1.41 to $1.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 21.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 21.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 103.43.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 5.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Pharmaceuticals (NASDAQ:CPRX) StockCatalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.Read More Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comHC Wainwright Comments on Catalyst Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:CPRX)March 22, 2023 | finance.yahoo.comWall Street Analysts Think Catalyst (CPRX) Could Surge 26.44%: Read This Before Placing a BetMarch 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 22, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Catalyst Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:CPRX)March 20, 2023 | benzinga.com4 Analysts Have This to Say About Catalyst PharmaceuticalsMarch 20, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN) and Catalyst Pharma (CPRX)March 20, 2023 | americanbankingnews.comCantor Fitzgerald Boosts Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $25.00March 19, 2023 | benzinga.comCheck Out What Whales Are Doing With CPRXMarch 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 18, 2023 | seekingalpha.comCatalyst Pharmaceuticals, Inc. (CPRX) Q4 2022 Earnings Call TranscriptMarch 18, 2023 | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Trading Up 5.7%March 17, 2023 | finance.yahoo.comIs It Worth Investing in Catalyst (CPRX) Based on Wall Street's Bullish Views?March 16, 2023 | finance.yahoo.com3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX)March 16, 2023 | markets.businessinsider.comWhy Catalyst Pharmaceuticals Shares Are MovingMarch 16, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 15, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitorsMarch 15, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 15, 2023 | finance.yahoo.comCatalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass EstimatesMarch 14, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms marketMarch 10, 2023 | finance.yahoo.comCatalyst Pharmaceuticals, Inc. (CPRX) is Attracting Investor Attention: Here is What You Should KnowMarch 8, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic EpilepsiesMarch 1, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock rises Wednesday, outperforms marketMarch 1, 2023 | finance.yahoo.comZacks.com featured highlights Lamb Weston, Catalyst Pharmaceuticals and Northeast Community BankMarch 1, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock outperforms market on strong trading dayMarch 1, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock falls Tuesday, underperforms marketMarch 1, 2023 | finance.yahoo.comCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023February 27, 2023 | finance.yahoo.comCatalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should KnowSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Company Calendar Last Earnings11/09/2021Today3/24/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees76Year Founded2002Price Target and Rating Average Stock Price Forecast$21.50 High Stock Price Forecast$25.00 Low Stock Price Forecast$15.50 Forecasted Upside/Downside+33.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.74 Trailing P/E Ratio21.78 Forward P/E Ratio11.43 P/E GrowthN/ANet Income$83.08 million Net Margins38.78% Pretax Margin48.89% Return on Equity32.21% Return on Assets27.17% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.45 Sales & Book Value Annual Sales$214.20 million Price / Sales7.95 Cash Flow$0.79 per share Price / Cash Flow20.40 Book Value$2.89 per share Price / Book5.58Miscellaneous Outstanding Shares105,650,000Free Float90,757,000Market Cap$1.70 billion OptionableOptionable Beta1.16 Social Links Key ExecutivesPatrick J. McEnanyChairman, President & Chief Executive OfficerSteven R. MillerChief Operating & Scientific OfficerAlicia GrandeCFO, Treasurer, Principal Accounting Officer & VPGary IngenitoChief Medical & Regulatory OfficerStanley IyaduraiVice President-Clinical DevelopmentKey CompetitorsFibroGenNASDAQ:FGENAmphastar PharmaceuticalsNASDAQ:AMPHAkero TherapeuticsNASDAQ:AKROPacira BioSciencesNASDAQ:PCRXXencorNASDAQ:XNCRView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 2,610 shares on 3/23/2023Ownership: 0.048%Brian ElsberndSold 50,000 sharesTotal: $803,500.00 ($16.07/share)B. Riley Wealth Advisors Inc.Bought 25,569 shares on 3/15/2023Ownership: 0.025%Voya Investment Management LLCSold 2,518 shares on 2/28/2023Ownership: 0.054%B. Riley Wealth Advisors Inc.Bought 25,569 shares on 2/21/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions CPRX Stock - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price forecast for 2023? 4 Wall Street research analysts have issued 1 year price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price forecasts range from $15.50 to $25.00. On average, they predict the company's share price to reach $21.50 in the next year. This suggests a possible upside of 34.2% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2023? Catalyst Pharmaceuticals' stock was trading at $18.60 at the beginning of 2023. Since then, CPRX shares have decreased by 13.9% and is now trading at $16.02. View the best growth stocks for 2023 here. Are investors shorting Catalyst Pharmaceuticals? Catalyst Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 10,370,000 shares, an increase of 6.5% from the February 13th total of 9,740,000 shares. Based on an average trading volume of 2,360,000 shares, the short-interest ratio is currently 4.4 days. Approximately 10.6% of the shares of the stock are sold short. View Catalyst Pharmaceuticals' Short Interest. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analysts' expectations of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 32.21% and a net margin of 38.78%. During the same quarter last year, the firm earned $0.11 earnings per share. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Aztlan Global Stock Selection DM SMID ETF (AZTD), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco DWA Healthcare Momentum ETF (PTH), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT) and Invesco S&P SmallCap Momentum ETF (XSMO). What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals issued an update on its fourth quarter 2022 earnings guidance on Tuesday, February, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $61.00 million-$61.00 million, compared to the consensus revenue estimate of $56.84 million. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.22%), Dimensional Fund Advisors LP (2.22%), Two Sigma Investments LP (1.85%), Two Sigma Advisers LP (1.74%), Geode Capital Management LLC (1.69%) and Morgan Stanley (1.67%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $16.02. How much money does Catalyst Pharmaceuticals make? Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.69 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $0.74 on an earnings per share basis. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933. This page (NASDAQ:CPRX) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.